Other OTC - Delayed Quote USD

Panbela Therapeutics, Inc. (PBLA)

0.4100 -0.0300 (-6.82%)
At close: April 26 at 3:27 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for PBLA

Recent News: PBLA

View More
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
GlobeNewswire 6 days ago
Panbela Announces Poster Presentation at American Association for Cancer Research:

Panbela Announces Poster Presentation at American Association for Cancer Research:
GlobeNewswire 10 days ago
Panbela Announces Transfer to OTCQB Market

Panbela Announces Transfer to OTCQB Market
GlobeNewswire 11 days ago
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results

Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
GlobeNewswire last month
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024

Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
GlobeNewswire last month
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
GlobeNewswire 2 months ago
Panbela Announces Closing of Approximately $9.0 Million Public Offering

Panbela Announces Closing of Approximately $9.0 Million Public Offering
GlobeNewswire 2 months ago
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
GlobeNewswire 2 months ago
Panbela Announces Pricing of Approximately $9.0 Million Public Offering

Panbela Announces Pricing of Approximately $9.0 Million Public Offering
GlobeNewswire 2 months ago
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
GlobeNewswire 3 months ago
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
GlobeNewswire 3 months ago
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024

Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
GlobeNewswire 3 months ago
View More

Related Tickers

RNAZ TransCode Therapeutics, Inc.
0.5499
+5.30%
 
DRMA Dermata Therapeutics, Inc.
0.3427
-3.74%
 
SPRC SciSparc Ltd.
1.3200
+4.76%
 
NEXI NexImmune, Inc.
3.3700
-1.17%
 
CDIO Cardio Diagnostics Holdings, Inc.
0.6900
-4.49%
 
ZVSA ZyVersa Therapeutics, Inc.
4.9900
-16.83%
 
ENSC Ensysce Biosciences, Inc.
0.5842
+1.69%
 
CING Cingulate Inc.
0.8801
+1.71%
 
FWBI First Wave BioPharma, Inc.
2.7400
+0.37%
 
MNPR Monopar Therapeutics Inc.
0.6582
+4.81%